Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

26.84USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$26.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
943,010
52-wk High
$32.49
52-wk Low
$14.23

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $7,940.70
Shares Outstanding(Mil.): 295.85
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Exelixis reports Q3 earnings per share $0.26

* Exelixis announces third quarter 2017 financial results and provides corporate update

Nov 01 2017

Exelixis drug improves overall survival in liver cancer patients

Exelixis Inc's drug to treat a type of liver cancer improved overall survival in patients in a late-stage study that prompted an independent expert group to recommend no further trial, sending the company's shares soaring 31 percent.

Oct 16 2017

UPDATE 3-Exelixis drug improves overall survival in liver cancer patients

* Shares jump 31 pct (Adds details, company comment, updates shares))

Oct 16 2017

BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial

* Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

Oct 16 2017

Exelixis cancer drug meets key goal in late-stage trial

Oct 16 Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer.

Oct 16 2017

BRIEF-Exelixis to receive milestone payment from Bristol-Myers Squibb

* Exelixis to receive milestone payment from Bristol-Myers Squibb for submission of clinical trial authorization for RORγt inverse agonist program

Oct 04 2017

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Sep 11 2017

BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer

* Exelixis submits U.S. Supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer Source text for Eikon: Further company coverage:

Aug 16 2017

BRIEF-Exelixis announces settlement of dispute with Genentech

* Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib

Jul 20 2017

BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial

* Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Jul 10 2017

Competitors

Earnings vs. Estimates